You are here: Home » Products » API » Anti-cancer APIS » Upadacitinib » Upadacitinib



CAS No.:1310726-60-3
Type:Pharmaceutical API
Certificate:GMP, COPP, WC, DMF
Shelf Life:2 years
Quality Standard:CP, EP, JP, USP
Chemical Name:(3S,4R)-3-ethyl-4-(1,5,7,10-tetrazatricyclo [,6]dodeca-2(6),3,7,9,11-pentaen-12-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
facebook sharing button
twitter sharing button
line sharing button
wechat sharing button
linkedin sharing button
pinterest sharing button
whatsapp sharing button
sharethis sharing button

Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by synovial inflammation and hyperplasia, autoantibody production, cartilage damage and bone destruction, leading to co-morbidities. Despite a variety of therapeutic agents available for treatment, up to 40% of the patients do not respond to current therapies, including biological therapies. The etiology of the disease is mostly unknown; however, the role of JAK as a driver of immune-mediated conditions was discovered, leading to the use of JAK as therapeutic targets for rheumatoid arthritis. To reduce dose-related toxicity (as seen with some pan-JAK inhibitors) without significantly affecting efficacy, more selective JAK1 inhibitors, upadacitinib and [filgotinib], were developed.


JAK Inhibition: Upadacitinib targets JAK1 and JAK2, which are enzymes involved in the signaling of certain cytokines, such as interleukins and interferons. These cytokines play critical roles in immune responses and inflammation. By inhibiting JAK1 and JAK2, Upadacitinib interferes with the signaling of pro-inflammatory cytokines, leading to a reduction in inflammation.

Rheumatoid Arthritis Treatment: Upadacitinib is primarily used for the treatment of moderate to severe rheumatoid arthritis in adult patients who have not responded adequately to or cannot tolerate conventional disease-modifying antirheumatic drugs (DMARDs) or biologic DMARDs. Rheumatoid arthritis is an autoimmune condition where the immune system attacks the joints, causing inflammation, pain, and joint damage. By inhibiting JAK1 and JAK2, Upadacitinib helps to alleviate the symptoms of rheumatoid arthritis and slow down the progression of joint damage.

Upadacitinib is available in tablet form and is usually taken orally. The dosage and duration of treatment depend on the specific condition being treated and the individual's response to the medication. It is essential to follow the prescribing doctor's instructions carefully when using Upadacitinib.


1kg/bag or 2kg/bag or 5kg/bag or 10kg/bag or according to customer’s requirements.

Related Products

Related News

content is empty!

Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.



Copyright © 2023 Shandong Loncom Pharmaceutical Co., Ltd. All Rights Reserved. Sitemap | Privacy Policy
Supported by leadong.com
Contact Us